GENCLIS
Genclis SA is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). TI is a patented process that begins by analyzing differences between RNA and DNA sequences to identify translated proteins capable of causing the production of either Immunoglobulin E (“IgE”), the antibody responsible for most forms of allergies or Immunoglobulin G (“IgG”), the workhorse of immunity that accounts for most of vaccine efficacy. Genclis uses its proprietary patented platform technology to develop therapies that elicit self-produced antibodies that block disease-causing proteins irrespective of their endogenous or exogenous origin.
GENCLIS
Industry:
Biotechnology Health Care
Founded:
2004-01-01
Address:
Nancy, Lorraine, France
Country:
France
Website Url:
http://www.genclis.com
Total Employee:
11+
Status:
Active
Contact:
+33 3 83 67 82 11
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
Egle Therapeutics
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Current Employees Featured
Official Site Inspections
http://www.genclis.com
- Host name: node45-eu.n0c.com
- IP address: 185.221.182.59
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Genclis"
Accueil - Genclis
Welcome to Genclis! I am proud to lead a team of highly skilled and enthusiastic scientists to tackle some of the most critical battles modern medicine faces. Patients first. At Genclis, curing people is our main mission. My life’s goal has …See details»
Genclis - Crunchbase Company Profile & Funding
Genclis SA is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). TI is a patented …See details»
Genclis Company Profile 2024: Valuation, Funding & Investors
Genclis General Information Description. Operator of a biotechnology company intended to discover, develop and commercialize diagnostic tests for cancer and allergy. The company's …See details»
Genclis Company Profile - Office Locations, Competitors ... - Craft
Genclis is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (TI). It commercializes pre-clinical and cellular models in …See details»
Genclis - Products, Competitors, Financials, Employees, …
Genclis is a biotechnology company focused on the development of alternate RNA derived therapeutics for drug discovery and development. The company has developed a technology …See details»
GENCLIS SA - LinkedIn
GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly …See details»
Genclis SAS - Company Profile and News - Bloomberg Markets
Company profile page for Genclis SAS including stock price, company news, executives, board members, and contact informationSee details»
GENCLIS Company Profile | VANDOEUVRE-LES-NANCY ... - Dun
Find company research, competitor information, contact details & financial data for GENCLIS of VANDOEUVRE-LES-NANCY, GRAND EST. Get the latest business insights from Dun & …See details»
GENCLIS SA Overview | SignalHire Company Profile
Organization Website: WWW.GENCLIS.COM : Phone Number: 0383678211: GENCLIS SA industries Biotech: Headquarters Location: 15, Rue du Bois de la Champelle, Vandoeuvre-lès …See details»
Genclis - Overview, News & Similar companies | ZoomInfo.com
Genclis revenues grew 500 % to €2.2 million in fiscal year 2017 missing breakeven by less than 10 %. Genclis' objectives for 2018 are to further expand commercial activities in both human …See details»
Genclis - VentureRadar
GENCLIS generates between 1 and 1.2 million Euros in revenue, with a profit greater than 20%. 2006 - GENCLIS organizes its first capital increase, in order to develop its own range of …See details»
Genclis - Crunchbase
Genclis is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). Search Crunchbase. Start Free Trial . Chrome …See details»
GENCLIS SA Information - RocketReach
GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). Transcription Infidelity is a newly …See details»
Genclis SA - Drug pipelines, Patents, Clinical trials - Synapse
Explore Genclis SA with its drug pipeline, therapeutic area, technology platform, .See details»
Genclis - Contacts, Employees, Board Members, Advisors & Alumni
Genclis is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). ... Products. Resources. Pricing. Resources. Log In. …See details»
Contact - Genclis
Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site web. Si vous continuez à utiliser ce site, nous supposerons que vous en êtes satisfait.See details»
Genclis - L'Usine Digitale
Genclis est une start-up française de biotechnologie qui développe et commercialise des tests de dépistage du cancer et d’allergies.. Elle est reconnue pour son expertise pharmaceutique ...See details»
Genclis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Genclis is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). Search Crunchbase. Start Free Trial . Chrome …See details»
What is Genclis? Company Culture, Mission, Values | Glassdoor
Genclis. Is this your company? This employer has not claimed their Employer Profile and is missing out on connecting with our community. Connect with our community. Claim your Free …See details»
RELIEF THERAPEUTICS Holding SA announces an in-licensing …
Genclis revenues grew >500 % to €2.2 million in fiscal year 2017 missing breakeven by less than 10 %. Genclis’ objectives for 2018 are to further expand commercial activities in both human …See details»